<DOC>
	<DOCNO>NCT00001805</DOCNO>
	<brief_summary>This phase II clinical pharmacokinetic study suppression human antimouse ( HAMA ) antitoxin antibody ( HATA ) immunotoxin LMB-1 Rituximab ( anti-CD20 ) . The primary objective study determine effect Rituximab HAMA HATA response LMB-1 administer patient advanced carcinoma express B3 antigen . Other objective include evaluation pharmacokinetics anti-tumor effect .</brief_summary>
	<brief_title>A Phase II Clinical Trial Suppression Human Antimouse Antibody Human Antitoxin Response Immunotoxin LMB-1 Rituximab</brief_title>
	<detailed_description>This phase II clinical pharmacokinetic study suppression human antimouse ( HAMA ) antitoxin antibody ( HATA ) immunotoxin LMB-1 Rituximab ( anti-CD20 ) . The primary objective study determine effect Rituximab HAMA HATA response LMB-1 administer patient advanced carcinoma express B3 antigen . Other objective include evaluation pharmacokinetics anti-tumor effect .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antitoxins</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>Patients must advance stage solid tumor histologically cytologically proven evaluable measurable disease refractory standard treatment malignancy effective standard therapy exist . Must presence B3 antigen surface great 30 % tumor cell . Must great equal 18 year old able give inform consent . Must ECOG performance status 0 1 minimum life expectancy 3 month . Must normal renal function ( Creatinine less equal 1.4 mg/dl ) , SGOT SGPT less equal 2.5 x upper limit normal . Total bilirubin le 1.5 mg/dL ; AGC great equal 1.5 x 10 ( 3 ) microliter ; platelet great 100,000 per mm ( 3 ) . Must recover toxic effect prior chemotherapy radiation therapy . At least 3 week must elapse since last dose chemotherapy , hormonal therapy radiation therapy . At least six week must elapse since last dose Mitomycin C nitrosourea . Must serum neutralize antibody LMB1 . Must positive hepatitis B surface antigen , hepatitis C antibody HIV . Must history coronary artery disease , NY class IIIV CHF , arrhythmia require treatment contraindication pressor therapy . Must FEV1 FVC less equal 65 % predict value . Must baseline serum albumin le 3.0 g/dl . Must history CNS metastasis and/or know seizure disorder , concurrent malignancy . Must acute bacterial infection require antibiotic therapy ( unless infection completely resolve ) . Must coexist medical psychiatric condition likely interfere study procedure and/or result . Must pregnant breastfeeding . Patients childbearing potential must agree use effective method contraception . Must history allergic reaction penicillin . Must lymphoma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2000</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
</DOC>